Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Melanoma 250Uveal Melanoma 29Neoplasm Metastasis 22Skin Neoplasms 17Brain Neoplasms 17Carcinoma, Non-Small-Cell Lung 15Carcinoma, Merkel Cell 10Neoplasms 9Carcinoma, Renal Cell 9Squamous Cell Carcinoma of Head and Neck 8Triple Negative Breast Neoplasms 7Carcinoma, Hepatocellular 7Uterine Cervical Neoplasms 6Colorectal Neoplasms 6Carcinoma, Transitional Cell 6Urinary Bladder Neoplasms 5Stomach Neoplasms 5Lung Neoplasms 5Diabetes Mellitus, Insulin-Dependent, 12 5Small Cell Lung Carcinoma 4Ovarian Neoplasms 4Kidney Neoplasms 4Carcinoma, Basal Cell 4Sarcoma 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Non-Hodgkin 3Liver Neoplasms 3Esophageal Neoplasms 3Endometrial Neoplasms 3Vulvar Neoplasms 2

Interventions

TH 302 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hypoxia × Ipilimumab × Dermatologic × Clear all
NCT03098160 2017-10-30

Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

Threshold Pharmaceuticals

Phase 1 Unknown
69 enrolled
DermatologicGastrointestinalGenitourinaryHead & Neck

Squamous Cell Carcinoma of Head and Neck, Hypoxia, Melanoma, Pancreatic Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡